Biofrontera AG (BFRA) 銘柄情報

* * $BFRA Video Chart 09-11-2020 * *

Link to Video - click here to watch the technical chart video

What's up here? This chart looks crazy.

what a reversal from the highs today

I WAIT FOR $55. LOL. IF BFRA DOESN'T GET THERE, THAT'S OK TOO.

12-14 dollars.

Officially dead...

New info needed for Monday

Can anyone translate the pdf ? News possibly monday? I'm short and need to cover if that's true

I got lucky today. Flipped a quick 40%. I'll be watching this tomorrow premarket. Good luck to you too! And stay safe.

I agree Pedro. I'm not touching this...GLTY

Yesterday's run caught my eye. But after watching the trading for a few hours yesterday and premarket today -- the run was being manipulated to dump shares.

Lol...you gotta love the single digit trades.

I think this is a scam company.

Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021
Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) has decided on 27 July 2020, with the approval of the Supervisory Board, to issue a 1.00 % qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454). It is divided into up to 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each and a total nominal value

Aug 10, 2020

www.globenewswire.com

https://www.dnb.com/business-directory/company-information.pharmaceutical-manufacturing.de.nordrhein-westfalen.leverkusen.html
German drug manufactures.

Got it. That makes sense, cutting china from the supply chain.

thanks.

Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com. Trump wants to eliminate China and India as our biggest generic drugs suppliers (80%) that's the whole reason with the Kodak disaster. Trump wants suppliers to be here or from some of his favorite countries, Germany being one of them. What I've just stated are facts. Just my opinion that something could happen here like Kodak as far as getting contracts for manufacturing but who knows...GLTY...BFRA

Apologies, not sure why my msg got posted twice.

But what does that have to do with BFRA?

Trump spoke yesterday about big pharma cost cutting and mentioned Germany.

yeah crazy is an understatement

DAILY

WEEKLY

BFRA HALTED FOR GOING CRAZY

15.44 > hod

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

International sales on approved dermatology products.

Super low float > less than 2M shares.

IPO > 2/14/18 > Biofrontera AG Announces Closing of $US12.9 Million Firm Commitment Initial Public Offering of American Depositary Shares
3 days 16 hours 56 minutes ago - DJNF
Biofrontera AG Announces Closing of $US12.9 Million Firm Commitment Initial Public Offering of American Depositary Shares
LEVERKUSEN, Germany, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) ("Biofrontera" or the "Company"), an international biopharmaceutical company, today announced the closing of a U.S. firm commitment underwritten public offering of American Depositary Shares ("ADSs"), at an offering price of $9.88 per ADS. Each ADS represents two of Biofrontera's ordinary shares, nominal value EUR1.00 per share. The Company sold a total of 1,300,483 ADSs, including a full exercise by the underwriters of the over-allotment option to purchase 85,483 ADSs, which option exercise also closed today. The ADSs began trading on The NASDAQ Capital Market under the symbol "BFRA" on February 14, 2018.

The Company received gross proceeds of approximately $12.9 million from the ADSs sold in this offering, before deducting underwriting discounts and commissions of approximately $1.0 million and other related expenses.

As previously announced, Biofrontera also separately completed a concurrent preemptive rights offering of its ordinary shares pursuant to German law to its existing holders of ordinary shares, under which Biofrontera will be issuing a total of 3,399,034 ordinary shares to the existing shareholders who exercised their subscription rights at an offering price of EUR4.00 per share (or approximately $4.94 per share, representing the same per share price as the one used in the ADS offering, adjusting for the ratio of ordinary shares to ADSs). In total, including the ordinary shares underlying the ADSs, the Company is issuing 6,000,000 new ordinary shares. The newly issued ordinary shares will trade on the Frankfurt Stock Exchange under the Company's existing listing of B8F.F.

Proceeds from these offerings will be used to expand Biofrontera's U.S. sales and marketing organization, fund additional clinical trials of its product Ameluz(R) (and to make regulatory filings for marketing approval of Ameluz(R), both for geographic expansion and the extension of the indications for Ameluz(R)), and for general corporate purposes.

The Benchmark Company, LLC acted as the managing underwriter with Dawson James Securities, Inc. and Lake Street Capital Markets acted as co-managers. Dawson James Securities, Inc. acted as the "qualified independent underwriter" as in connection with this offering.

A registration statement on Form F-1 relating to this U.S. offering was filed with the Securities and Exchange Commission ("SEC") and was declared effective by the SEC as of February 13, 2018. The U.S. offering of these securities was made only by means of a prospectus, forming a part of the registration statement. The registration statement on Form F-1 and the final prospectus relating to the U.S. offering are available on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the U.S. offering may be obtained from Biofrontera, with an address of Hemmelrather Weg 201, D-51377, Leverkusen, Germany Telephone: +011 49 214 876 00, email: press@biofrontera.com. In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.biofrontera.com. In addition, you may contact The Benchmark Company by calling 212-312-6700 or prospectus@benchmarkcompany.com.

McGuireWoods LLP acted as U.S. legal counsel to Biofrontera, and Schiff Hardin LLP acted as legal counsel to the underwriters.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, the securities described above, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.

Enquiries, please contact:

Biofrontera AG +49 (0) 214 87 63 2 0

Thomas Schaffer, Chief Financial Officer press@biofrontera.com

IR Germany: Brainwell Asset Solutions

Jürgen Benker +49 (0) 152 08931514

IR UK: Seton Services

Toni Vallen +44(0) 20 7729 0805

IR and PR US: The Ruth Group

IR: Tram Bui +1 646-536-7035

PR: Kirsten Thomas +1 508-280-6592

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.